1996
DOI: 10.1021/bc9600628
|View full text |Cite
|
Sign up to set email alerts
|

Antibody Fragments in Tumor Pretargeting. Evaluation of Biotinylated FabColocalization with Recombinant Streptavidin and Avidin

Abstract: An evaluation of the use of a biotinylated monoclonal antibody Fab' fragment in tumor pretargeting was conducted. As a model system, tumor colocalization of avidin or recombinant streptavidin (r-streptavidin) and the biotinylated Fab' fragment (Fab'-S-biotin) of A6H, an antirenal cell carcinoma antibody, was evaluated in athymic mice bearing human renal cell carcinoma xenografts. A new water soluble sulfhydryl reactive biotinylation reagent, N-(13-N-maleimdo-4, 7,10-trioxatridecanyl)-biotinamide, was synthesiz… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
87
0

Year Published

1998
1998
2013
2013

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 62 publications
(87 citation statements)
references
References 33 publications
0
87
0
Order By: Relevance
“…Biodistribution data were obtained by determining the presence of the co-injected radionuclides in a panel of tissues harvested at sacri®ce (24, 72, 120 and 168 h post-injection) as previously described in detail. 14 …”
Section: Xenografts and Biodistributionmentioning
confidence: 99%
“…Biodistribution data were obtained by determining the presence of the co-injected radionuclides in a panel of tissues harvested at sacri®ce (24, 72, 120 and 168 h post-injection) as previously described in detail. 14 …”
Section: Xenografts and Biodistributionmentioning
confidence: 99%
“…This pretargeting approach has been demonstrated to improve the ratios of radiation delivered to tumors compared with the doses delivered to normal organs in preclinical and clinical models. [12][13][14][15][16][17][18][19][20][21][22][23][24] Recent work using human carcinoma xenografts demonstrated that a single treatment of pretargeted 90 Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-biotin resulted in rapid effective blood clearance of non-tumorbound antibody, improved tumor-to-normal organ ratios of absorbed radioactivity, and superior objective and durable remissions with minimal toxicity. 25 Synthetic clearing agents have been introduced as an additional refinement to pretargeting protocols to more efficiently deplete immunoconjugates lingering in the bloodstream before administration of the radioactive moiety.…”
Section: Introductionmentioning
confidence: 99%
“…The biotinamido amine 7 was synthesized and characterized as described previously. [18] 3-[N-(D-Biotinoyl)-13-amino-4,7,10-trioxatridecanylaminocarbonyl]propanoic acid (8 a). A solution of the biotinamido amine 7 (2.80 g, 6.3 mmol) in dry DMF (20 mL) was reacted with succinic anhydride (688 mg, 6.88 mmol), and the solution was stirred at room temperature for 1 h under N 2 atmosphere.…”
Section: Tri-o-acetyl-2-deoxy-2-fluoro-d-xylopyranose (4) a Solutionmentioning
confidence: 99%